Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thirdmeinvestor thirdmeinvestor Nov 27, 2012 4:50 PM Flag

    GILDreport

    All remaining patients, 22% = 100 - 78%, relapsed after the treatment is over. I am certain that the SVR12 is NOT a cure, and there would be more relapsers when the SVR24 or SVR48 is measured. The 12 wk 7977/RVB regimen is not viable except for the people who cannot tolerate peg/RBV.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sorry, but the science overwhelmingly supports SVR12. The support was validated during the approval of both PIs actually. 22% relapse would be terrible if the SVR was 50%... but if everyone who doesn't hit SVR relapses.. that is actually pretty good. It just means the virus was nearly eradicated but there was not quite enough drug pressure to do so. If there was say 12% relapse, but 10% failure on-treatment, it would be worse... that would mean the virus is escaping despite constant pressure. 12 weeks is very close here and actually viable for more than just PR intolerant folks. I have no skin in this now... just know the science too well to see these statements that could be misleading to people. I am sure it was not ill-intentioned. It is a complex beast.

 
VRTX
81.67-0.23(-0.28%)12:42 PMEDT